Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 11;35(7):789-812.
doi: 10.1515/revneuro-2024-0045. Print 2024 Oct 28.

The impact of genetic factors on the response to migraine therapy

Affiliations
Review

The impact of genetic factors on the response to migraine therapy

Daniil Tsirelis et al. Rev Neurosci. .

Abstract

Migraine is a multidimensional disease affecting a large portion of the human population presenting with a variety of symptoms. In the era of personalized medicine, successful migraine treatment presents a challenge, as several studies have shown the impact of a patient's genetic profile on therapy response. However, with the emergence of contemporary treatment options, there is promise for improved outcomes. A literature search was conducted in PubMed and Scopus, in order to obtain studies investigating the impact of genetic factors on migraine therapy outcome. Overall, 23 studies were included in the current review, exhibiting diversity in the treatments used and the genetic variants investigated. Divergent genes were assessed for each category of migraine treatment. Several genetic factors were identified to contribute to the heterogeneous response to treatment. SNPs related to pharmacodynamic receptors, pharmacogenetics and migraine susceptibility loci were the most investigated variants, revealing some interesting significant results. To date, various associations have been recorded correlating the impact of genetic factors on migraine treatment responses. More extensive research needs to take place with the aim of shedding light on the labyrinthine effects of genetic variations on migraine treatment, and, consequently, these findings can promptly affect migraine treatment and improve migraine patients' life quality in the vision of precise medicine.

Keywords: acute migraine therapy; genetic factors; migraine genetics; polymorphisms; prophylactic migraine therapy.

PubMed Disclaimer

References

    1. Amiri, P., Kazeminasab, S., Nejadghaderi, S.A., Mohammadinasab, R., Pourfathi, H., Araj-Khodaei, M., Sullman, M.J.M., Kolahi, A.-A., and Safiri, S. (2022). Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front. Neurol. 12: 800605, https://doi.org/10.3389/fneur.2021.800605 . - DOI
    1. Asuni, C., Cherchi, A., Congiu, D., Piccardi, M.P., Del Zompo, M., and Stochino, M.E. (2007). Association study between clinical response to rizatriptan and some candidate genes. J. Headache Pain 8: 185–189, https://doi.org/10.1007/s10194-007-0388-5 . - DOI
    1. Atasayar, G., Eryilmaz, I.E., Karli, N., Egeli, U., Zarifoglu, M., Cecener, G., Taskapilioglu, O., Tunca, B., Yildirim, O., Ak, S., et al.. (2016). Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. J. Neurol. Sci. 366: 149–154, https://doi.org/10.1016/j.jns.2016.05.019 . - DOI
    1. Aynacioglu, A.S., Sachse, C., Bozkurt, A., Kortunay, S., Nacak, M., Schröder, T., Kayaalp, S.O., Roots, I., and Brockmöller, J. (1999). Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 66: 185–192, https://doi.org/10.1053/cp.1999.v66.100072001 . - DOI
    1. Barbanti, P., Fofi, L., Aurilia, C., and Egeo, G. (2013). Dopaminergic symptoms in migraine. Neurol. Sci. 34(Suppl. 1): S67–S70, https://doi.org/10.1007/s10072-013-1415-8 . - DOI

MeSH terms

LinkOut - more resources